Monday, November 21st, 2022

09:00-13:00: Pre-conference workshop – Bridging across methods in the biosciences (BeAMs): the opportunity of COVID-19
Chairs: Dr Annamaria Carusi & Dr Sofia Batista Leite

Tuesday, November 22nd, 2022

8:30-10:30: Session 2a – Models, biomarkers and assays for endocrine disruption and developmental toxicity
Ingrid Langezaal – Upcoming validated mechanistic in vitro methods for the identification of thyroid disruptors

14:00-16:00: Session 4a – Computational toxicology – in silico modelling, read-across, artificial intelligence and machine learning
Donatella Carpi – Modelling in vitro time-concentration response of gene expression to chemical exposure

Wednesday, November 23rd, 2022

11:00-13:00: Session 6b – Knowledge sharing and education
João Barroso – Scientific Validity of Non-Animal-Derived Antibodies

Thursday, November 24th, 2022

08:30-10:30: Session 7a – Developmental Neurotoxicity (DNT)
Laure-Alix Clerbaux – effects of spike protein and toxin-like peptides found in covid-19 patients on human 3d neuronal/glial model undergoing differentiation: possible sars-cov-2 implications for brain development

08:30-10:30: Session 7b – Implementation of NAMs into regulatory frameworks – establishing scientific confidence, development of standards and good practices
Sandra Coecke – Method developers are key players ensuring in-house reproducibility and relevance of in vitro methods paving the way for regulatory acceptance

11:00-12:40: Session 8b – In vitro COVID-19 research / Lung and cardiovascular models
Sandra Coecke – Knowledge from Human Relevant Cell, Tissue and Mathematics-based Methods as Key Tools for Understanding COVID-19 Dynamics, Kinetics, Symptoms, Risk Factors and Non-conventional Treatments

Poster sessions

Poster Session: 2a. Models, biomarkers and assays for endocrine disruption and developmental toxicity
Sandra Coecke – Investigation on the reproducibility of the DIO1 inhibition in vitro method based on human liver microsomes (Poster #)
Anne Milcamps – Validation of Endocrine Disrupter Assays at EURL ECVAM (Poster P-2a-15)

Poster Session: 8b. In vitro COVID-19 research / Lung and cardiovascular models
Laure-Alix Clerbaux – Intestinal Adverse Outcomes in COVID-19: Current evidence and Uncertainties using the Adverse Outcome Pathway Framework (Poster P-8b-2)